Clinical Trials Directory

Trials / Sponsors / Kastle Therapeutics, LLC

Kastle Therapeutics, LLC

Industry · 18 registered clinical trials.

StatusTrialPhaseStarted
CompletedA Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hyperchol
Hypercholesterolemia, Heterozygous Familial
Phase 32011-12-01
CompletedStudy to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
Healthy Volunteer
Phase 12011-09-01
CompletedA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese H
Healthy Volunteer
Phase 12011-01-01
CompletedA Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharm
Healthy
Phase 12010-05-01
CompletedA Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects
Healthy
Phase 12010-03-01
CompletedA Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Heal
Healthy Volunteer
Phase 12010-01-01
CompletedSafety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-
Hypercholesterolemia, Coronary Heart Disease
Phase 32009-01-01
CompletedSafety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients
Hypercholesterolemia, Coronary Heart Disease
Phase 32008-11-01
CompletedSafety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
Metabolic Diseases, Hyperlipidemias, Metabolic Disorder
Phase 22008-10-01
CompletedEfficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With
Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
Phase 32008-07-01
CompletedAn Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patie
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias
Phase 32008-04-01
CompletedStudy to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemi
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias
Phase 32007-07-01
CompletedOpen Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias
Phase 22007-05-01
CompletedMeasure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases
Phase 22006-07-01
CompletedStudy of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering The
Hypercholesterolemia, Familial
Phase 22006-02-01
CompletedDose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowe
Hypercholesterolemia, Familial
Phase 22006-01-01
CompletedDose-escalating Safety Study in Subjects on Stable Statin Therapy
Hypercholesterolemia
Phase 22005-09-01
CompletedSafety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels
Hypercholesterolemia
Phase 22005-08-01